Department of Radiology, Sumitomo Hospital, Osaka, Japan.
Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
J Vasc Surg. 2023 Jun;77(6):1751-1759. doi: 10.1016/j.jvs.2023.01.207. Epub 2023 Feb 14.
To compare the results of endovascular treatment with drug-eluting stents (DES) and drug-coated balloons (DCB) in atherosclerotic lesions in the femoropopliteal artery, as well as to assess restenotic patterns.
Clinical data from 617 cases treated with DES or DCB for femoropopliteal diseases were analyzed in this multicenter, retrospective cohort study. From these, 290 DES and 145 DCB cases were extracted by propensity score matching. Outcomes investigated were 1- and 2-year primary patency, reintervention, and restenotic pattern and its impact on symptoms in each group.
The primary patency rates at 1 and 2 years in the DES group were superior to those in the DCB group (84.8% and 71.1% vs 81.3% and 66.6%, P = .043), whereas there was no significant difference in freedom from target lesion revascularization (91.6% and 82.6% vs 88.3% and 78.8%, P = .13). Compared with what was measured before the index procedures, exacerbated symptoms, rate of occlusion, and an increase in the occluded length at loss of patency were more frequent in the DES group than in the DCB group. The odds ratios were 3.53 (95% confidence interval, 1.31-9.49; P = .012), 3.61 (1.09-11.9; P = .036), and 3.82 (1.15-12.7; P = .029), respectively. On the other hand, the frequency of an increase in lesion length and requirement of target lesion revascularization were similar between the two groups.
Primary patency was significantly higher at 1 and 2 years in the DES than in the DCB group. However, DES were associated with exacerbated clinical symptoms and complicated lesion characteristics at the point of loss of patency.
比较药物洗脱支架(DES)和药物涂层球囊(DCB)治疗股腘动脉粥样硬化病变的结果,并评估再狭窄模式。
本多中心回顾性队列研究分析了 617 例接受 DES 或 DCB 治疗股腘疾病的患者的临床数据。通过倾向评分匹配,从这些患者中提取了 290 例 DES 和 145 例 DCB 病例。研究的结局包括 1 年和 2 年的一期通畅率、再次介入治疗和再狭窄模式及其对每组症状的影响。
DES 组的 1 年和 2 年一期通畅率优于 DCB 组(84.8%和 71.1%比 81.3%和 66.6%,P=0.043),但无靶病变血运重建率无显著差异(91.6%和 82.6%比 88.3%和 78.8%,P=0.13)。与指数治疗前相比,DES 组在失功时更频繁地出现症状加重、闭塞率增加和闭塞长度增加。优势比分别为 3.53(95%可信区间,1.31-9.49;P=0.012)、3.61(1.09-11.9;P=0.036)和 3.82(1.15-12.7;P=0.029)。另一方面,两组之间病变长度增加的频率和需要靶病变血运重建的频率相似。
DES 在 1 年和 2 年时的一期通畅率明显高于 DCB 组。然而,DES 与失功时临床症状恶化和病变特征复杂有关。